FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model

Islets. Jul-Aug 2010;2(4):247-51. doi: 10.4161/isl.2.4.12402.

Abstract

To clarify the effect of fibroblast growth factor-21 (FGF-21) on islet transplantation, a suboptimal number of islets were transplanted into streptozotocin (STZ)-induced diabetic mice with or without FGF-21 treatment. Three-day treatment with FGF-21 contributed to restoration of normoglycemia by suppressing islet graft loss. The FGF-21-treated mice showed lower glycemic levels despite similar insulin content in the graft than that in untreated mice on day 3, indicating that FGF-21 not only has a cytoprotective effect but also decreases β-cell load by increasing insulin sensitivity. These results suggest that FGF-21 may be useful as a treatment to improve islet engraftment rates in clinical islet transplantation.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / analysis
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetes Mellitus, Experimental / therapy
  • Fibroblast Growth Factors / pharmacology*
  • Fibroblast Growth Factors / therapeutic use
  • Glucose Tolerance Test
  • Insulin / blood
  • Insulin / metabolism
  • Insulin Secretion
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / metabolism
  • Islets of Langerhans / physiopathology
  • Islets of Langerhans Transplantation / methods*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Models, Animal
  • Streptozocin
  • Transplantation Conditioning / methods
  • Transplantation, Isogeneic

Substances

  • Blood Glucose
  • Insulin
  • fibroblast growth factor 21
  • Streptozocin
  • Fibroblast Growth Factors